|
Name |
Aspergixanthone C
|
Molecular Formula | C27H30O9 | |
IUPAC Name* |
[(1R,2S)-11-hydroxy-5-methyl-12-oxo-2-prop-1-en-2-yl-8-[(1R,2R)-1,2,3-trihydroxy-3-methylbutyl]-2,3-dihydro-1H-pyrano[3,2-a]xanthen-1-yl] acetate
|
|
SMILES |
CC1=CC2=C(C3=C1OC[C@@H]([C@H]3OC(=O)C)C(=C)C)C(=O)C4=C(C=CC(=C4O2)[C@H]([C@H](C(C)(C)O)O)O)O
|
|
InChI |
InChI=1S/C27H30O9/c1-11(2)15-10-34-23-12(3)9-17-19(20(23)25(15)35-13(4)28)22(31)18-16(29)8-7-14(24(18)36-17)21(30)26(32)27(5,6)33/h7-9,15,21,25-26,29-30,32-33H,1,10H2,2-6H3/t15-,21-,25-,26-/m1/s1
|
|
InChIKey |
MSUKKAKNJDCWOC-RMMNZIBASA-N
|
|
Synonyms |
Aspergixanthone C
|
|
CAS | NA | |
PubChem CID | 156581703 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 498.5 | ALogp: | 3.0 |
HBD: | 4 | HBA: | 9 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 143.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 36 | QED Weighted: | 0.232 |
Caco-2 Permeability: | -5.478 | MDCK Permeability: | 0.00000843 |
Pgp-inhibitor: | 0.062 | Pgp-substrate: | 0.986 |
Human Intestinal Absorption (HIA): | 0.344 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.004 |
Blood-Brain-Barrier Penetration (BBB): | 0.018 | Plasma Protein Binding (PPB): | 81.64% |
Volume Distribution (VD): | 1.283 | Fu: | 12.91% |
CYP1A2-inhibitor: | 0.089 | CYP1A2-substrate: | 0.259 |
CYP2C19-inhibitor: | 0.031 | CYP2C19-substrate: | 0.106 |
CYP2C9-inhibitor: | 0.513 | CYP2C9-substrate: | 0.784 |
CYP2D6-inhibitor: | 0.067 | CYP2D6-substrate: | 0.153 |
CYP3A4-inhibitor: | 0.181 | CYP3A4-substrate: | 0.172 |
Clearance (CL): | 1.397 | Half-life (T1/2): | 0.186 |
hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.917 |
Drug-inuced Liver Injury (DILI): | 0.959 | AMES Toxicity: | 0.701 |
Rat Oral Acute Toxicity: | 0.671 | Maximum Recommended Daily Dose: | 0.77 |
Skin Sensitization: | 0.151 | Carcinogencity: | 0.507 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.029 |
Respiratory Toxicity: | 0.03 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004145 | 0.694 | D0Q0PR | 0.257 | ||||
ENC002651 | 0.634 | D0K8KX | 0.248 | ||||
ENC002697 | 0.609 | D0O6KE | 0.237 | ||||
ENC002544 | 0.581 | D0F7CS | 0.236 | ||||
ENC002623 | 0.579 | D04AIT | 0.232 | ||||
ENC002341 | 0.561 | D06GCK | 0.231 | ||||
ENC005491 | 0.515 | D0FX2Q | 0.231 | ||||
ENC006093 | 0.483 | D04UTT | 0.225 | ||||
ENC002916 | 0.483 | D08LTU | 0.220 | ||||
ENC004537 | 0.466 | D0J5TS | 0.218 |